title: Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?
abstract: OBJECTIVE
  The goals of this study were to: (1) systematically evaluate patient preferences regarding side effects of high-dose chemotherapy with stem cell support for treatment of advanced ovarian cancer; and (2) assess whether patients' preferences changed over time.
  
  
  METHODS
  Forty patients with stage III or IV disease were enrolled in this study. Patients' preferences regarding 12 health states (side effects) were assessed using visual analogue scale (VAS) and time trade-off (TTO) methods during mobilization chemotherapy (T(1)) and 6-7 weeks later after high-dose chemotherapy and stem cell transplant (T(2)). Each assessment involved a 45-min interview conducted at the patient's bedside.
  
  
  RESULTS
  The three most preferred health states were no evidence of disease (NED), a chemotherapy with few or no side effects, and alopecia, while the least preferred health states were chemotherapy with multiple severe side effects, hepatotoxicity, and nausea and vomiting. These results were observed at both T(1) and T(2) using both preference assessment methods. Pancytopenia scores significantly increased from T(1) to T(2) using the VAS method (P < 0.05), but decreased using the TTO method.
  
  
  CONCLUSIONS
  Chemotherapy-experienced women with ovarian cancer have consistent preferences for the best and worst health states associated with the side effects of chemotherapy. Patients are more averse to nausea and vomiting than many other symptoms. Women's perceptions of pancytopenia may be dependent upon the number of prior cycles of chemotherapy and site of care for anemia, thrombocytopenia, and febrile neutropenia.
authors.affiliation: Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 440, Houston, TX 77030, USA. ccsun@mdanderson.org
authors.forename: Charlotte C
authors.initials: CC
authors.lastname: Sun
authors.forename: Diane C
authors.initials: DC
authors.lastname: Bodurka
authors.forename: Michele L
authors.initials: ML
authors.lastname: Donato
authors.forename: Edward B
authors.initials: EB
authors.lastname: Rubenstein
authors.forename: Candice L
authors.initials: CL
authors.lastname: Borden
authors.forename: Karen
authors.initials: K
authors.lastname: Basen-Engquist
authors.forename: Mark F
authors.initials: MF
authors.lastname: Munsell
authors.forename: John J
authors.initials: JJ
authors.lastname: Kavanagh
authors.forename: David M
authors.initials: DM
authors.lastname: Gershenson
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000523:psychology* / Q000628:therapy; D010147:Pain Measurement; D010342:Patient Acceptance of Health Care / Q000523:psychology; D017060:Patient Satisfaction; D033581:Stem Cell Transplantation
chemical_list: D000970:Antineoplastic Agents